Crowdonomics
WatchlistPortfolio
All companies

Medicus Pharma Ltd.

Raising nowPublic

Biotech · W. Conshohocken, PA

Medicus Pharma is a clinical-stage, multi-strategy holding company that invests in and speeds up the development of novel life sciences and biotechnology companies through FDA-approved clinical trials. It holds the SkinJect technology through a 2023 reverse takeover.

Raising nowRaising now on Maxim Group LLC

This company has an open fundraising round.

$0 raised
View the live round
Estimated pre-money ⓘ
$60.4M
As of Mar 2025 · from Reg A Offering (2025) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$11,017,500
Crowd $0 · Private $11.0M · 2 rounds since 2024
Latest share price
$4.25
Reg A+ · Equity · Mar 2025 offering price

Financials

FY2023–FY2025 · from SEC filings · hover any figure for its source
$0
−$5.3M
2023
−$11.2M
2024
−$47.3M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2023 audited
FY2024 audited
FY2025 audited
Income statement
Revenue
$0
—
—
Cost of goods sold
$8,830,197
—
—
Net income
-$5,314,765
-$11,155,516
-$47,281,513
Taxes paid
$0
$0
$0
Balance sheet
Cash
$1,719,338
$4,164,323
$8,705,218
Accounts receivable
$0
—
—
Total assets
$1,893,057
$5,646,878
$10,061,377
Short-term debt
—
$0
$5,245,543
Long-term debt
$0
—
—
Total liabilities
$781,609
$2,512,174
$10,024,066
Other
Headcount
12
—
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$60.4M
est. pre-money
Reg A+ · Equity · Mar 2025

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Apr 4, 2025
ClassOutstandingVotes / shareShare of totalLast price
Common Shares13,417,5611100.0%$4.25Mar 2025

Shares outstanding over timein today's share terms

13M6.7M0
Feb 2025Apr 2025
Common Shares

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Apr 29, 2026

  • Dr. Kenneth Melani3,323,741 Common Shares7.9%of company
  • Ajay Raju2,031,250 Common Shares4.9%of company
  • Dr. Raza Bokhari1,343,173 Common Shares3.2%of company
  • Carolyn Bonner166,405 Common Shares—of votes
  • Edward Brennan268,000 Common Shares—of votes
  • Faisal Mehmud175,000 Common Shares—of votes
  • Hon. Cathy McMorris Rodgers31,250 Common Shares—of votes
  • Larry Kaiser71,250 Common Shares—of votes
  • Patrick Mahaffy66,685 Common Shares—of votes
  • Robert J. Ciaruffoli83,750 Common Shares—of votes
  • Sara R. May71,250 Common Shares—of votes
  • William Ashton72,500 Common Shares—of votes
  • Andrew Smith125,164 Common Shares—of votes
  • Barry Fishman71,250 Common Shares—of votes

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Mar 2025Openvia Maxim Group LLC
Raised $0 / $22.7MEst. pre-money $60.4M
Rule 506(b) · Equity · May 2024Closed
Raised $11MInvestors 23

Team

11 people
Dr. Raza Bokhari (3)
Executive Chairman and Chief Executive Officer
Carolyn Bonner
President
Dr. Edward Brennan
Chief Scientific Officer & Head of R&D Program
Dr. Faisal Mehmud
Chief Medical Officer
James Quinlan
Chief Financial Officer
Barry Fishman (4) (5)
Director
Dr. Larry Kaiser (1) (5)
Director
Dr. Sara R. May (2)
Director
Frank Lavelle (1) (2) (4)
Director
Show 2 more people
Robert J. Ciaruffoli (1) (2) (3)
Director
William L. Ashton (2) (3) (4) (5)
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

View all 43 filings on EDGAR
  • Form 10-QAug 12, 20260001062993-26-004230
    EDGAR
  • Form 10-QMay 14, 20260001062993-26-002629
    EDGAR
  • Form 10-K/AApr 29, 20260001062993-26-002212
    EDGAR
  • Form 10-KMar 25, 20260001062993-26-001606
    EDGAR
  • Form 253G2Mar 6, 20260001062993-26-001328
    EDGAR
  • Form 253G2Dec 30, 20250001062993-25-017498
    EDGAR
  • Form 253G2Dec 8, 20250001062993-25-017235
    EDGAR
  • Form 253G2Dec 1, 20250001062993-25-017097
    EDGAR
Source: SEC EDGARCIK 0001997296Ontario, CanadaShare price $4.25Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.